Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT03692663
Last Updated: 2022-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
9 participants
INTERVENTIONAL
2018-12-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
NCT07156045
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07298239
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
NCT05354375
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
NCT05521412
PD1 Integrated Anti-PSMA CART in Treating Patients With Castrate-Resistant Prostate Cancer
NCT04768608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TABP EIC treatment group
Drug: TABP EIC Experimental Interventional Therapy
TABP EIC
A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
Cyclophosphamide
Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
fludarabine
Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TABP EIC
A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
Cyclophosphamide
Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
fludarabine
Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. diagnosed metastatic castration-resistant prostate cancer (mCRPC);
2. Castration level of serum testosterone (\< 50 ng/dL or \< 1.7 nmol/L);
3. Positive expression of PSMA;
4. According to the definition of CRPC in the Guidelines for the Diagnosis and Treatment of Prostate Cancer (2022 edition), the disease still progresses after castration and meets any of the following criteria:
A.According to the increase in PSA level, there should be 3 consecutive increases in PSA at least 1 week apart (the increase in PSA is more than 50% of the minimum value, and PSA \> 2 ng/mL); B.Progression of bone disease as defined by PCWG3, defined as the presence of 2 or more new lesions on bone scan; C.CT or MRI results suggested measurable metastasis (lymph node short diameter \> 15 mm was defined as lymph node metastasis as assessed by RECIST 1.1);
5. Expected survival time ≥6 months;
6. Toxicity of any previous treatment had recovered to ≤ grade 1 at the time of enrollment (except hair loss and hearing loss);
7. ECOG score of patients 0-1;
8. Patients voluntarily participated and signed the informed consent, and followed the trial treatment plan and visit plan.
Exclusion Criteria
1. Previous recipients of other cell therapy products, such as dendritic cells (DC), multiple cytokine-induced killer cells (CIK), T cells, natural killer cells (NK), chimeric antigen receptor T-cell immunotherapy (CAR-T), etc.;
2. Previous treatment with any PSMA-targeted therapy;
3. radiotherapy was administered within 4 weeks prior to the start of study treatment;
4. Patients with a history of biological macromolecule drug allergy;
5. Abnormal function of major organs:
A. Neutrophil count (ANC) \< 1.5×109/L; Platelet count (Plt) \< 100×109/L; Hemoglobin (Hb) \< 9 g/dL; B. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN (≥5×ULN for liver metastases); C. Renal function: serum creatinine (Cr) ≥1.5×ULN; D. Prothrombin time (PT) \> 15 s, activated partial thrombin time (APTT) was prolonged or shortened by more than 10 s (normal reference value 23 s-37 s), or international normalized ratio (INR) \> 1.7; E. Pulmonary function: Severe respiratory diseases (active pulmonary tuberculosis, chronic obstructive pulmonary disease, interstitial lung disease, etc.)
6. Patients required systemic long-term steroid use or had received systemic steroids (dose equivalent to prednisone \>10 mg/ day, except for patients using inhaled hormones) or other immunosuppressive agents 30 days before enrollment;
7. A history of severe central nervous system disorders, such as stroke or epilepsy;
8. active autoimmune diseases (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis) or need long-term immunosuppressive therapy of severe autoimmune disease (screening clinic within six weeks before any immunosuppressive therapy), or by the researchers determine in 3 months will be recurrence of subjects;
9. have had other malignancies other than prostate cancer (other than basal or squamous cell skin cancer) in the past 5 years that are currently clinically significant and require intervention;
10. Clinically significant heart disease (New York Heart Association class III/IV, left ventricular ejection fraction \< 60%);
11. Any active (viral, bacterial, fungal) infection currently being treated or any infection requiring intravenous antibiotics for 7 or more days or intervals during the past 6 weeks or any active infection requiring oral antibiotics during the past 1 week;
12. untreated chronic active hepatitis B, or chronic hepatitis B virus carriers with HBV DNA≥1000 copies /mL, or active hepatitis C patients;
13. Patients who have participated in other clinical trials and used study drugs within 3 months;
14. In the opinion of the investigator, there are other factors that are not suitable for inclusion or affect the participant's participation or completion of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin People's Hospital
OTHER
Allife Medical Science and Technology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huaqing Wang, Doctor
Role: PRINCIPAL_INVESTIGATOR
Oncology of Tianjin people's hospital, 190 Jianyuan Road, Hongqiao District, Tianjin
Jian Li, Doctor
Role: PRINCIPAL_INVESTIGATOR
Urinary surgeryof Tianjin people's hospital, 190 Jianyuan Road, Hongqiao District, Tianjin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin pepole's hosptial
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TABP EIC-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.